Weikel CA, Breton J, Butler D, West J, et al. Characterization of isolates from two phase 3 uncomplicated urinary tract infection trials (EAGLE-2 and EAGLE-3) that show an apparent >/=4-fold increase in gepotidacin MIC between baseline and post-baseline visits. JAC Antimicrob Resist 2026;8:dlag186.
PMID: 42682990